Lupus & antiphospholipid syndrome
SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis
Authors' conclusion
Monitoring urinary BAFF-bioactivity may be valuable in diagnosing LN. Furthermore, stratification based on serum BAFF and IFN-I bioactivities may allow the identification of appropriate patients for biologics targeting BAFF and IFN-I.
Study context
- Population
- SLE patients and healthy controls
- Comparison
- SLE patients stratified by serum BAFF and IFN-I bioactivity; LN vs non-LN vs healthy controls
Methodological detailsreporter cell assay, publicly available scRNA-seq data, immunohistological analysis
- Reporter cell assay
- Publicly available scRNA-seq data
- Immunohistological analysis
Main finding
As reported in the abstract
- SLE patients, especially LN, had significantly higher serum BAFF-bioactivity than healthy controls (HC) and non-LN patients
- BAFF expressed in glomerular macrophages and mesangial cells in LN kidney samples (scRNA-seq and immunohistology)
- Urinary BAFF bioactivity elevated in LN vs non-LN; no IFN-I bioactivity detected in urine
- Stratification by serum BAFF and IFN-I: high BAFF represented LN; high IFN-I represented blood and skin manifestations
Original publication
SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis. Rheumatology (Oxford). Published 12 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →